Tokyo, Aug. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062560) titled 'A Prospective Observational Study of Atogepant Effectiveness in Routine Clinical Practice in Japan' on Aug. 12.
Study Type:
Observational
Primary Sponsor:
Institute - AbbVie GK
Condition:
Condition - Migraine
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate patient-reported improvement with atogepant for the prevention of migraine.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 15
years-old
=15 at time of informed consent. If the patient is under 18 years old, a patient's parent or legal guardian must be willing to give written informed co...